Calidi Biotherapeutics, Inc. Proceeds from (Repayments of) Related Party Debt
Calidi Biotherapeutics, Inc. (CLDI) reported Proceeds from (Repayments of) Related Party Debt of $2.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt · last filed 2025-03-31
- Calidi Biotherapeutics, Inc. proceeds from (repayments of) related party debt for the quarter ending 2023-12-31 was $0.00.
- Calidi Biotherapeutics, Inc. proceeds from (repayments of) related party debt for the quarter ending 2023-09-30 was $0.00.
- Calidi Biotherapeutics, Inc. proceeds from (repayments of) related party debt for the quarter ending 2023-06-30 was $400.00K.
- Calidi Biotherapeutics, Inc. proceeds from (repayments of) related party debt for the quarter ending 2023-03-31 was $1.60M.
- Calidi Biotherapeutics, Inc. proceeds from (repayments of) related party debt for fiscal 2023 was $2.00M, a 100.00% increase from fiscal 2022.
- Calidi Biotherapeutics, Inc. proceeds from (repayments of) related party debt for fiscal 2022 was $1.00M.
| Period end | Proceeds from (Repayments of) Related Party Debt 3 month | Proceeds from (Repayments of) Related Party Debt 6 month | Proceeds from (Repayments of) Related Party Debt 9 month | Proceeds from (Repayments of) Related Party Debt 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $400.00K derived: sum of 3 quarters · filed 2025-03-31 | $2.00M 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $400.00K derived: sum of 2 quarters · filed 2024-11-12 | $2.00M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.00M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $1.60M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $1.00M 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |